Investor Relations

Recent Event

Fiscal Year 2022 Conference Call

Treosulfan Pivotal Study Results with Dr. Filippo Milano, MD

Email Alerts

Receive updates straight into your inbox

Sign up Today

Investor Contact Information

Company

Medexus Pharmaceuticals, Inc.
35 Nixon Rd Unit 1
Bolton, ON L7E 1K
Canada

Investor Relations (Canada)

Adelaide Capital
Victoria Rutherford
T: 480-625-5772
Victoria@adcap.ca

Direct Financial Strategies and Communication Inc.
Frank Candido
T: 514-969-5530
frank.candido@medexus.com

Company Overview

Medexus Pharmaceuticals, Inc. is a leading innovative and rare disease pharmaceutical company with a strong North American commercial platform. The Company’s vision is to provide the best healthcare products to healthcare professionals and patients, through our core values of Quality, Innovation, Customer Service and Collaboration. Medexus is focused on the therapeutic areas of rheumatology, auto-immune disease, specialty oncology and pediatrics. The leading prescription products are Rasuvo and Metoject, a unique formulation of methotrexate (auto-injector and pre-filled syringe) designed to treat rheumatoid arthritis and other auto-immune diseases; and Rupall, an innovative allergy medication with a unique mode of action.